Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score

Gastroenterology. 2022 Oct;163(4):1104-1106.e3. doi: 10.1053/j.gastro.2022.06.057. Epub 2022 Jun 28.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antiviral Agents / adverse effects
  • Carcinoma, Hepatocellular* / diagnosis
  • Carcinoma, Hepatocellular* / epidemiology
  • Carcinoma, Hepatocellular* / etiology
  • Hepacivirus / genetics
  • Hepatitis C* / complications
  • Hepatitis C* / diagnosis
  • Hepatitis C* / drug therapy
  • Hepatitis C, Chronic* / complications
  • Hepatitis C, Chronic* / diagnosis
  • Hepatitis C, Chronic* / drug therapy
  • Humans
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / diagnosis
  • Liver Cirrhosis / drug therapy
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / epidemiology
  • Liver Neoplasms* / etiology

Substances

  • Antiviral Agents